Virus-Immunotherapy combo targets Hard-to-Treat cancers

NCT ID NCT05165433

First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This early-phase study tested a new treatment called NG-350A, a virus designed to activate immune cells inside tumors, combined with the immunotherapy drug pembrolizumab. It involved 14 people with advanced epithelial cancers that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of this combination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Churchill Hospital, Oxford University Hospitals NHS Foundation Trust

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Moffitt-Advent Health Clinical Research Unit

    Celebration, Florida, 34747, United States

  • Perelman Center of Advanced Medicine

    Philadelphia, Pennsylvania, 19104, United States

  • Providence Medical Foundation

    Santa Monica, California, 90404, United States

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Liverpool, Lancashire, L7 8YA, United Kingdom

  • UCLA

    Santa Monica, California, 90404, United States

Conditions

Explore the condition pages connected to this study.